<DOC>
	<DOC>NCT00002218</DOC>
	<brief_summary>To determine the maximum tolerated dose of CI-1012 in late-stage HIV-1-infected patients. To determine the antiretroviral activity of CI-1012 when added to combination therapy. To assess the multiple-dose pharmacokinetic characteristics of CT-1012 when added to combination therapy. To assess the effect of CI-1012 on the pharmacokinetics of other antiretroviral agents.</brief_summary>
	<brief_title>A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients</brief_title>
	<detailed_description>Doses are escalated based on safety assessments: As soon as a dose meets the criteria for "tolerated" or "not tolerated", doses are escalated or terminated, respectively. All patients are treated for 2 weeks, with follow-up visits scheduled 1 week and 1 month post-treatment.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Patients must have: Serological evidence of latestage HIV1 infection (ELISA and Western Blot). CD4 T cell count less than or equal to 200 mm3. HIV1 RNA greater than or equal to 5,000 copies/mL. Exclusion Criteria Prior Medication: Excluded: AntiHIV treatment within 8 weeks prior to entry. Systemic steroids within 4 weeks prior to entry. Prior Treatment: Excluded: Treatment with anticancer agents within 4 weeks prior to study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 1998</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Dose-Response Relationship, Drug</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>